March 2024
1. GRUNT TW, Wagner R, Ries A, Berghoff AS, et al
   Targeting endogenous fatty acid synthesis stimulates the migration of ovarian cancer cells to adipocytes and promotes the transport of fatty acids from adipocytes to cancer cells.
   Int J Oncol. 2024;64:24.
   

   >> Share

   
   
2. GENG D, Zhou Y, Wang M
   Advances in the role of GPX3 in ovarian cancer (Review).
   Int J Oncol. 2024;64:31.
   

   >> Share

   
   
3. INOUE F, Sone K, Kumegawa K, Hachijo R, et al
   Inhibition of protein arginine methyltransferase 6 activates interferon signaling and induces the apoptosis of endometrial cancer cells via histone modification.
   Int J Oncol. 2024;64:32.
   

   >> Share

   
   January 2024
4. LIU Y, Yang Y, Wang X, Yin S, et al
   Function of microRNA?124 in the pathogenesis of cancer (Review).
   Int J Oncol. 2024;64:6.
   

   >> Share

   
   December 2023
5. QI Y, Ma N, Zhang J
   Tripartite motif containing 33 demonstrated anticancer effect by degrading c?Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells.
   Int J Oncol. 2023;63:133.
   

   >> Share

   
   
6. LIANG T, Lu T, Jia W, Li R, et al
   Knockdown of lncRNA MALAT1 induces pyroptosis by regulating the miR?124/SIRT1 axis in cervical cancer cells.
   Int J Oncol. 2023;63:138.
   

   >> Share

   
   November 2023
7. DENG F, Fu M, Zhao C, Lei J, et al
   Calcium signals and potential therapy targets in ovarian cancer (Review).
   Int J Oncol. 2023;63:125.
   

   >> Share

   
   October 2023
8. YUAN J, Guan W, Li X, Wang F, et al
   RBM15‑mediating MDR1 mRNA m(6)A methylation regulated by the TGF‑beta signaling pathway in paclitaxel‑resistant ovarian cancer.
   Int J Oncol. 2023;63:112.
   

   >> Share

   
   September 2023
9. O'DONNELL J, Zhao Z, Buckingham L, Hao T, et al
   Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo.
   Int J Oncol. 2023;63:103.
   

   >> Share

   
   August 2023
10. ZHAI L, Yang X, Dong J, Qian L, et al
    O‑GlcNAcylation mediates endometrial cancer progression by regulating the Hippo‑YAP pathway.
    Int J Oncol. 2023;63:90.
    

    >> Share

    
    May 2023
11. CHEN Q, Shen S, Lv N, Tong J, et al
    Role of microRNAs in glycolysis in gynecological tumors (Review).
    Int J Oncol. 2023;62:63.
    

    >> Share

    
    December 2022
12. KARIN-KUJUNDZIC V, Covarrubias-Pinto A, Skrtic A, Vranic S, et al
    New insight into the role of PTCH1 protein in serous ovarian carcinomas.
    Int J Oncol. 2022;61.
    

    >> Share

    
    
13. SHEN S, Guo J, Lv N, Chen Q, et al
    RNA m6A methylation regulators in endometrial cancer (Review).
    Int J Oncol. 2022;61.
    

    >> Share

    
    November 2022
14. ENDO Y, Sugimoto K, Kobayashi M, Kobayashi Y, et al
    Claudin9 is a novel prognostic biomarker for endometrial cancer.
    Int J Oncol. 2022;61.
    

    >> Share

    
    October 2022
15. WANG Y, Han A, Chen E, Singh RK, et al
    [Corrigendum] The cranberry flavonoids PAC DP9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.
    Int J Oncol. 2022;61.
    

    >> Share

    
    
16. LI R, Wang Y, Xu Y, He X, et al
    [Retracted] Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
    Int J Oncol. 2022;61.
    

    >> Share

    
    
17. BJERSAND K, Blom K, Poromaa IS, Stalberg K, et al
    Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome.
    Int J Oncol. 2022;61.
    

    >> Share

    
    
18. KIM SH, Baek KH
    Ovarian tumor deubiquitinase 6A regulates cell proliferation via deubiquitination of nucleolin and caspase7.
    Int J Oncol. 2022;61.
    

    >> Share

    
    July 2022
19. XU L, Li J, Tursun M, Hai Y, et al
    Receptor for activated C kinase 1 promotes cervical cancer lymph node metastasis via the glycolysisdependent AKT/mTOR signaling.
    Int J Oncol. 2022;61.
    

    >> Share

    
    
20. FEDIER A, Maggi N, Tozzi A, Disler M, et al
    Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Int J Oncol. 2022;61.
    

    >> Share

    
    May 2022
21. ZHANG R, Roque DM, Reader J, Lin J, et al
    Combined inhibition of IL6 and IL8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
22. LAVORO A, Scalisi A, Candido S, Zanghi GN, et al
    Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    Int J Oncol. 2022;60.
    

    >> Share

    
    March 2022
23. LI L, Yu J, Duan Z, Dang HX, et al
    [Corrigendum] The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
24. SINGH T, Neal A, Dibernardo G, Raheseparian N, et al
    Efficacy of birinapant in combination with carboplatin in targeting platinumresistant epithelial ovarian cancers.
    Int J Oncol. 2022;60.
    

    >> Share

    
    January 2022
25. FAN LX, Tao L, Lai YC, Cai SY, et al
    Cx32 promotes autophagy and produces resistance to SNinduced apoptosis via activation of AMPK signalling in cervical cancer.
    Int J Oncol. 2022;60.
    

    >> Share

    
    July 2021
26. FALZONE L, Scandurra G, Lombardo V, Gattuso G, et al
    A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
    Int J Oncol. 2021;59.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share